Effectiveness of 0.1% triamcinolone acetonide compared with those of other therapies for minor recurrent aphthous stomatitis: a systematic review and meta-analysis of randomized controlled trials Authors: Anas Saeed Al-Zaghruri, Mohammed M. Al Moaleem, Ahmed Yaseen Alqutaibi, Abbas Ahmed Abdulqader, Baleegh Abdulraoof Al-Kadasi, Nashwan Abduljabbar Noman, Ayman Ali Saad, Ammar Ahmed Al-Hiagem, Magdi Abdullah Abdulsalam Published: 2025 ABSTRACT BackgroundRecurrent aphthous stomatitis (RAS) is a common oral mucosal condition affecting over 2.5 billion people worldwide. Although 0.1% triamcinolone acetonide is a standard treatment, its comparative efficacy remains uncertain.ObjectiveTo evaluate and compare systematically the efficacy of 0.1% triamcinolone acetonide with those of alternative therapies for RAS management.MethodsA systematic review and meta-analysis were conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. From December 2024 to April 2025, PubMed and the Cochrane Central Register of Controlled Trials, Semantic Scholar, and ScienceDirect were searched for randomized controlled trials (RCTs) evaluating 0.1% triamcinolone acetonide in minor RAS treatment. Eligible studies reported the outcomes of pain reduction, ulcer size, or healing time. Risk of bias was assessed by using the Cochrane Risk of Bias Tool, and meta-analysis pooled estimates were calculated by employing a random effects model.ResultsTwenty-five RCTs involving 1474 participants were included. Thyme honey, sumac gel, and laser therapies were significantly more effective than 0.1% triamcinolone acetonide in reducing pain and ulcer size. CBD oil, hyaluronic acid, curcumin, amlexanox, and nanoformulated triamcinolone exhibited comparable efficacies as 0.1% triamcinolone acetonide. The outcomes under chamomile, acemannan, and doxycycline benzocaine gel treatments were less favorable than those under 0.1% triamcinolone acetonide treatment. Laser therapy, sumac gel, and Punica granatum extract significantly reduced healing time compared with 0.1% triamcinolone acetonide. The meta-analysis demonstrated that 0.1% triamcinolone acetonide was significantly more effective than thyme honey, Rhus coriaria gel, and nanobased triamcinolone in reducing ulcer size and shortened healing time compared with Salvizan and P. granatum gels. However, no significant effect was observed in pain reduction when 0.1% triamcinolone acetonide was compared with either other treatments or the placebo, and no significant difference in healing time was found when 0.1% triamcinolone acetonide was compared with the placebo.ConclusionNatural agents, such as honey, sage, and sumac gel, show promise as effective, safe alternatives to 0.1% triamcinolone acetonide in the treatment of minor RAS, especially in patients intolerant to corticosteroids. While 0.1% triamcinolone acetonide significantly reduced ulcer size and shortened healing time compared with several alternative treatments, it demonstrated no significant advantage in pain reduction or healing time over the placebo. The results of this work should be interpreted with caution because of the limited number of placebo-controlled trials and the moderate-to-high risk of bias in the included studies.RegistrationWe registered our review protocol in PROSPERO under the ID CRD42024573362Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-025-07358-4. Introduction Recurrent aphthous stomatitis (RAS) is a common oral condition characterized by painful recurring ulcers that can impair patients’ quality of life [1]. It affects about 20% of the general population, occurring more often in females during childhood and adolescence [1, 2]. RAS is usually self-limiting, with lesions healing spontaneously [2]. Based on size and number, RAS is classified as minor, major, or herpetiform. Minor RAS, accounting for about 80% of cases, usually presents as one to five ulcers (3–10 mm) that heal within 4–14 days without scarring [3, 4]. Clinically, these ulcers appear as white or gray areas with a red halo, mainly on nonkeratinized mucosa [5]. Although the exact cause of RAS is unknown [6], several factors have been linked to its development, including immune dysregulation [7], nutritional deficiencies, hormonal changes, allergies, genetics, infections, stress, and systemic diseases such as Behçet’s, Crohn’s disease, and anemia [1, 8]. Histopathological features include epithelial ulceration, necrosis, and inflammatory cell infiltration, with perivascular inflammation and vascular changes contributing to lesion formation [9–11]. The main goal in managing active RAS is to relieve pain and reduce ulcer recurrence [12]. Treatment aims to ease discomfort and prolong the ulcer-free period through various topical and systemic approaches [13]. Topical agents such as anti-inflammatory drugs, antibiotics, and corticosteroids are preferred for their safety, effectiveness, and minimal systemic effects [14, 15]. Common options include local anesthetics like lidocaine for pain relief [16] and antiseptic mouthwashes with chlorhexidine, tetracycline, or minocycline, often combined with topical corticosteroids to control inflammation [17]. Supportive rinses with saline, sodium bicarbonate, or hydrogen peroxide may also help [18]. In severe or recurrent cases, systemic immunosuppressants such as colchicine, dapsone, or cyclosporine can be used, though side effects limit their use [19]. Recent evidence suggests that Chinese patent medicines may reduce pain, ulcer size, and recurrence [20], while low-dose laser therapy [21] and curcumin [22] have shown promising results. Triamcinolone acetonide, a moderate corticosteroid, remains a commonly used treatment for RAS [23]. Minor RAS represents the most common and clinically significant subtype of aphthous ulcers, accounting for most cases encountered in dental practice. Although triamcinolone acetonide has long been regarded as the standard topical therapy for minor RAS, recent years have seen the emergence of various alternative interventions, such as herbal formulations [24–26], low-level laser therapy (LLLT), and other anti-inflammatory agents, that may offer comparable or improved outcomes. Focusing on minor RAS is clinically relevant because it constitutes the form most frequently managed with topical therapies and has the greatest impact on patients’ comfort and quality of life. Clarifying how triamcinolone acetonide performs relative to these alternatives can therefore guide practitioners in selecting the most effective and safe treatment strategies [27]. Prolonged use of triamcinolone acetonide may cause local adverse effects such as mucosal thinning, Candida overgrowth, drug resistance, and, in rare cases, systemic complications like Cushing’s syndrome and osteoporosis. Short-term use, however, is generally safe [28, 29]. Although the exact etiology and pathogenesis of RAS remain unclear and no definitive treatment exists, triamcinolone acetonide has been widely used as a control and is considered a standard therapy in previous studies. This study aims to evaluate whether 0.1% triamcinolone acetonide provides superior outcomes in patients with minor RAS compared with other topical agents or placebo. Specifically, it investigates its effectiveness in relieving pain, reducing ulcer size, and shortening healing time. Through a systematic review and meta-analysis of randomized controlled trials (RCTs), this study seeks to clarify whether triamcinolone remains the most effective and reliable treatment for minor RAS. Methods Protocol and registration This review was conducted in strict accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses [30]. The protocol of this systematic review has been registered in the International Prospective Register of Systematic Reviews with the identifier CRD42024573362. Information sources Electronic searches were conducted in December 2024 and last updated in April 2025. A comprehensive search was performed across multiple databases, including PubMed and the Cochrane Central Register of Controlled Trials, Semantic Scholar, and ScienceDirect. Two authors independently performed searches in these databases. Additionally, manual searches were conducted in relevant journals that publish research on RAS and triamcinolone acetonide. Eligibility criteria This review included RCTs that compared 0.1% triamcinolone acetonide with other treatments for minor RAS. All participants had no systemic disease. Articles that were not available in English and those reporting on animal studies, studies focusing on the triamcinolone treatment of extraoral ulcerations and wounds like oral aphthous ulcers with systematic disease, retrospective studies, cases, and studies with incomplete data or lacking control groups were excluded in accordance with the exclusion criteria for this review. Search strategy A comprehensive literature search was conducted by using a combination of controlled vocabulary and free-text terms. The following keywords were used: “oral ulcer,” “aphthous stomatitis,” “canker sores,” “triamcinolone,” and “corticosteroid.” Additional terms included “minor,” “aphthous,” “recurrent,” “stomatitis,” “ulceration,” and “RAS.” The Boolean operators AND and OR were employed to combine search terms appropriately, as shown in Table 1. Table 1Search strategy and MeSH/keywords usedData setsTerminology that usedSearch dateNumber of articlesCochrane Central LibraryTriamcinolone OR corticosteroid AND recurrent aphthous ulcers OR canker sores OR recurrent aphthous stomatitis Title, Abstract, Keyword2025-04-10(n = 132)PubMed([triamcinolone] OR [corticosteroid]) AND ([{recurrent aphthous ulcers} OR [recurrent aphthous stomatitis] OR [canker sores]) OR [RAS]) OR [minor aphthous ulcer]2025-04-09(n = 904)SEMANTIC SCHOLAR(triamcinolone) OR (corticosteroid) AND (recurrent aphthous ulcers) OR (recurrent aphthous stomatitis) OR (canker sores) OR (RAS) OR (minor aphthous ulcer)2025-04-11(n = 384)ScienceDirect“triamcinolone” OR “corticosteroid” AND “oral ulcer” OR “aphthous stomatitis” OR “canker sores” OR “recurrent aphthous stomatitis”2025-04-10(n = 313) Table 1Search strategy and MeSH/keywords usedData setsTerminology that usedSearch dateNumber of articlesCochrane Central LibraryTriamcinolone OR corticosteroid AND recurrent aphthous ulcers OR canker sores OR recurrent aphthous stomatitis Title, Abstract, Keyword2025-04-10(n = 132)PubMed([triamcinolone] OR [corticosteroid]) AND ([{recurrent aphthous ulcers} OR [recurrent aphthous stomatitis] OR [canker sores]) OR [RAS]) OR [minor aphthous ulcer]2025-04-09(n = 904)SEMANTIC SCHOLAR(triamcinolone) OR (corticosteroid) AND (recurrent aphthous ulcers) OR (recurrent aphthous stomatitis) OR (canker sores) OR (RAS) OR (minor aphthous ulcer)2025-04-11(n = 384)ScienceDirect“triamcinolone” OR “corticosteroid” AND “oral ulcer” OR “aphthous stomatitis” OR “canker sores” OR “recurrent aphthous stomatitis”2025-04-10(n = 313) Search strategy and MeSH/keywords used Selection Papers were selected on the basis of the PICO framework, focusing on patients with RAS as the population (P); the use of triamcinolone as the intervention (I); other treatments or placebo as the comparison (C); and the efficacy of treatments in improving RAS lesions, measured by pain scales, lesion size reduction, and lesion healing time, as the outcome (O). Data collection Two independent reviewers extracted the data by using a standardized form. Discrepancies were resolved through discussion or third-party adjudication. Data were double-checked for consistency and accuracy. Data items The following data were collected: study characteristics (author, year, country), intervention and comparator details, outcome measures, and sample size per group. Primary outcomes included pain reduction, ulcer size reduction, and healing duration. Secondary outcomes encompassed time to pain recovery, severity of ulcers, satisfaction of patients, number of ulcers, erythema, exudation, quality of life, burning sensation, oral health impact profile, degree of ulcer healing, and occurrence of new ulcers. Summary measures and synthesis of results Outcomes were summarized on the basis of the efficacy of 0.1% triamcinolone acetonide compared with those of other interventions, with some studies including a placebo group. Data were synthesized to evaluate the overall effectiveness of 0.1% triamcinolone acetonide in treating minor RAS. Effect measures The following effect measures were employed on the basis of the collected pain scores (typically measured by using the Visual Analog Sacle [VAS] or a similar numerical scale), lesion size reduction (measured in millimeters), and healing time (number of days until full lesion resolution). Meta-analysis pooling was performed to determine the comparative efficacy of 0.1% triamcinolone acetonide against those of other interventions and the placebo. Risk of bias in individual studies The quality of the included RCTs was independently assessed by two authors by using the Cochrane Risk of Bias Tool Version 2 (ROB2) [31]. This tool evaluates the risk of bias across five key domains: (1) bias arising from randomization; (2) bias due to deviations from intended interventions; (3) bias caused by missing outcome data; (4) bias in the measurement of the outcome; and (5) bias in the selection of the reported result. For each domain, a judgment of low risk, some concerns, or high risk was assigned. On the basis of these domain-level assessments, an overall risk of bias judgment was made for each study. Results Selection of studies Study selection was executed in three distinct stages. In the initial stage, an initial search yielded 1733 articles. After title screening and duplicate record removal, 1217 articles were excluded. During the second stage, 516 of the remaining 385 articles were discarded because of the lack of relevant data in their abstracts. In the final stage, 131 articles were subjected to full-text review on the basis of the predetermined inclusion and exclusion criteria. Six articles were excluded because they reported studies that were not RCTs, resulting in 25 articles [11, 32–55] being selected for the review, as shown in Fig. 1. Fig. 1Flow chart of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow chart of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Study characteristics The 25 included RCTs comprised healthy individuals diagnosed clinically with minor RAS. Triamcinolone treatment groups included 631 participants, whereas comparator and placebo groups comprised 658 and 185 participants, respectively. Ages ranged from 15 years to 65 years. Female participants comprised approximately 60% of the study population. Studies were conducted in diverse geographic settings, with follow-up periods ranging from two days to 10 days. Detailed characteristics are shown in Table 2. Table 2Characteristics of the studies included, presented in descending order Author (S)., year/country Sample Size Blinding Age (Range) Treatment No of parts/ Outcome analysis Main results Frequency per dayDuration(N) daysTreatment groups/Dose Rezvani et al., 2025/Iran [33]30Triple-blinded18–5647Triamcinolone acetonide/0.1%201-Pain intensity (VAS)0-1002-Ulcer size3-Healing timeSumac paste led to the shortest healing time, smaller lesion size, and lower pain scores versus Triamcinolone and placebo and Triamcinolone had the longest healing time.Rhus coriaria gel20Placebo19Ghalwash et al., 2024/Egypt [32]60Single-blindedNM37Triamcinolone acetonide/0.1%151-Pain intensity (VAS)0-1002-Ulcer size3-Oral Health Impact Profile (OHIP-14)Thyme honey significantly reduced ulcer size compared to triamcinolone acetonide on days 5 and 7, with greater pain reduction on days 3, 5, and 7, and lower OHIP scores at day 7.Thyme honey15 Nayak et al., 2023/India [34]50Double-blinded18–604–510Triamcinolone acetonide/0.1%251-Pain intensity2-Ulcer size3-Ulcer severityTriamcinolone and Hiora SG gel showed significant reductions in pain, pain duration, and ulcer severity (p = 0.001), with no significant difference between themHiora SG gel25 Abbasi et al., 2023/Iran [35]60Double-blinded18–5037Triamcinolone acetonide/0.1%301-Healing time2-Time of Pain recoveryThe Salvizan group demonstrated a faster recovery, with shorter mean durations of pain relief and wound healing as well as compared with the triamcinolone acetonide group.Salvizan gel30 Umpreecha et al., 2023/ Thailand [36]72Double-blinded18–6537Triamcinolone acetonide/0.1%241-Pain intensity (VAS)0-1002-Ulcer size3-Ulcer severity4-quality-of-life questionnaire (OHIP-14).CBD and triamcinolone both reduced ulcer size more than placebo at all time points. CBD showed greater erythema reduction than placebo on day 2, while triamcinolone did so at all time points. Pain was lower with CBD vs placebo on day 5, and with triamcinolone vs placebo on days 4, 5, and 7. CBD group reported higher satisfaction, but OHIP-14 scores were similar across groupsTopical cannabidiol/0.1%24Placebo24 Lavaee, et al., 2022/Iran [37]22Single-blindedNM36Triamcinolone acetonide/0.1%111-Pain intensity (VAS)0-102-Ulcer sizeRhus coriaria and triamcinolone showed no significant intergroup differences, but both significantly reduced pain and lesion size; reductions were more consistent across all time points in the Rhus coriaria group.Rhus coriaria11Dhopte et al., 2022/India [38]60Unblinded15–50410Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Erythema4-Healing score5-Qulity of lifeBy day 3, the Low-level laser therapy group showed significantly greater pain and erythema reduction and better ulcer healing than the Triamcinolone group. Ulcer size reduction was similar between groups on days 3 and 5, with complete healing in both groups by day 10.1Low-level laser therapy/810 nm wavelength, 6.3 J/cm30Remash et al., 2021/India [39]30NA18–3037Triamcinolone acetonide/0.1%151-Pain intensity (NRS)2-Ulcer size3-Degree of ulcer healing4-Occurrence of New UlcersOn day 3, pre‑and probiotic sand hyaluronic acid had significantly lower pain scores than Hyaluronic acid and Triamcinolone (P = 0.04 and 0.01). By day 7, pre‑and probiotics and hyaluronic acid showed the highest wound closure (93.4 ± 2.5%) and greatest pain reduction (0.2 ± 0.42), but these differences were not statistically significant (P >0.05).3Hyaluronic acid/0.2%152Capsule of pre‑and probiotics & hyaluronic acid/0.2%15 Huo et al., 2021/China [40]56Unblinded18 and above 5133Triamcinolone acetonide/ 0.1%281-Pain intensity (VAS)0-102-Healing timeDiode laser reduced pain more effectively than Triamcinolone, with minimal advantage on wound healing comparing with Triamcinolone . .1Diode laser/wavelength of 810 nm and fiber diameter of 320 μm28 Seyyedi et al., 2020/ Iran [41]15Double-blinded17–6047Triamcinolone acetonide/0.1%51-Pain intensity (VAS)0-102-Ulcer sizeCO₂ laser (pulsed and continuous) reduced pain significantly effectively than Triamcinolone (P<0.05) but showed no significant effect on ulcer size.Continuous laser/power of 1 W and pulse duration of 5–10 s5Pulsed CO2 laser/power of 261 W and pulse duration of 180 ms5 Kia et al., 2020/Iran [42]58Double-blindedNM310Triamcinolone acetonide/0.1%29 1-Pain intensity (VAS)0-10 2-Ulcer sizeNo significant differences between the two groups in pain severity, lesion size.Curcumin/5 %29 Raman, et al., 2020/ India [43]69Unblinded18–3037Triamcinolone acetonide/0.1%351-Pain intensity (NIPC)0-5 2-Ulcer sizeTriamcinolone and Curcumin showed significant pain and size reduction (P<0.001).Curcumin/10mg34 Mirzaee et al., 2019/ Iran [44]60Triple-blindedNM47Triamcinolone acetonide/0.1%281-Pain intensity (VAS)0-1002-Ulcer sizePain intensity decreased in both NT and CT groups, with similar final scores. Lesion size reduced in both groups, but NT showed significantly greater reduction on days 2 & 4.Nanobased triamcinolone/0.1%27 Giroh et al., 2019/India [45]37Single‑blinded20–5037Triamcinolone acetonide/0.1%171-Pain intensity (VAS)0-102-Ulcer size3-Burning sensationTriamcinolone healed ulcers faster, while aloe vera gel provided better pain and burning relief.Topical aloe vera gel17 Tavangar et al., 2019/ Iran [46]60Double-blinded18–5035Triamcinolone acetonide/0.1%201-Ulcer size2-Healing time3-Time of Pain recoveryPunica granatum gel achieved faster pain relief compared with the placebo group, whereas the Triamcinolone group did not differ significantly from placebo. Furthermore, wound healing time was significantly shorter in the Punica granatum gel than in both the TriamcinolonePunica granatum gel20Placebo20 Sharma et al., 2018/India [47]50Double-blindedNM410Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer size3-Number ulcers4-Erythema 5-Exudate LevelsTriamcinolone acetonide 0.1% and amlexanox 5% were most effective in reducing ulcer size, number, pain, erythema, and exudate by days 8 and 10 (P=.000), outperforming doxycycline, benzocaine, and placebo. Doxycycline and benzocaine showed significant pain relief on the VAS scale.Amlexanox/5%10Benzocaine gel/20%10Doxycycline hyclate/100 mg10Placebo10 Shrivastava et al., 2018/India [48]40Double-blinded18–4545Triamcinolone acetonide/0.1%201-Pain intensity (VAS)0-102-Ulcer size3-Healing time4-ErythemaTriamcinolone had greater peri-ulcer erythema and pain reduction, while complete healing was slightly higher in the amlexanox groupAmlexanox 5%20 Ofluoglu et al., 2017/Turkey [11]180Doubleblinded18–6547Triamcinolone acetonide/0.1%601-Pain intensity (VAS)0-10 2-Ulcer sizeTGO group showed significantly lower pain scores on days 2, 4, and 6, with higher pain improvement rates on days 2 and 4, and greater ulcer size reduction on days 4 and 6 compared to the other groups. Demographics and ulcer history were similar across groups.Triester glycerol oxide60Placebo60NM Koray et al., 2016/Turkey [49]60UnblindedNM47Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-10Hyaluronic acid gel reduced RAS pain more effectively than TA, with significantly lower VAS scores on days 4 and 7.Hyaluronic acid30 Tadbir et al., 2015/Iran [50]43Double- blinded18–4636Triamcinolone acetonide/0.1%141-Pain intensity (VAS)2-Ulcer size3-Healing time4-Satisfaction of patients.Both triamcinolone and chamomile in Orabase reduced ulcer size by day 3 and pain by days 3 and 6 compared with placebo. Triamcinolone was more effective than chamomile and placebo in reducing ulcer size by day 6 and shortening healing time, while chamomile provided pain relief and high patient satisfaction.Chamomile14Placebo15 El-Haddad et al., 2014/Saudia Arabia [51]94Double- blinded18–6038Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Erythema4-Number of ulcersHoney significantly reduced ulcer size, pain duration, and erythema compared to topical corticosteroid and Orabase, with no reported side effects, confirming its effectiveness and safety for minor aphthous ulcers.Honey34Placebo30Deshmukh et al., 2014/India [52]60Double-blinded13–6637Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Healing time4-Number of ulcersBoth groups showed significant improvement in ulcer size, pain, number, and duration over 7 days, but there was no significant difference between them in treating RAS.Curcumin/10mg30Halim, et al., 2014/Malaysia[53]20Single-blinded18 and above25Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer SizeNo significant differences were observed between groups, but virgin coconut oil showed a trend toward greater ulcer size reduction and pain relief compared to triamcinolone.Virgin coconut oil10Halim et al., 2013/Malaysia [54]20Single-blinded18 and above25Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer sizeBoth treatments were equally effective in relieving pain and reducing the size of recurrent aphthous ulcers, with no significant differences between them.Turmeric powder10 Bhalang, et al., 2013/ Thailand [55]180Double-blinded18–6537Triamcinolone acetonide/0.1%601-Pain intensity (VAS)0-100 2-Ulcer sizeAcemannan caused no allergic reactions or side effects and showed better pain and ulcer size reduction than control, though less effective than 0.1% triamcinolone acetonide. Patient satisfaction was highest with triamcinolone and acemannan.Acemannan/0.560Placebo60 Table 2Characteristics of the studies included, presented in descending order Author (S)., year/country Sample Size Blinding Age (Range) Treatment No of parts/ Outcome analysis Main results Frequency per dayDuration(N) daysTreatment groups/Dose Rezvani et al., 2025/Iran [33]30Triple-blinded18–5647Triamcinolone acetonide/0.1%201-Pain intensity (VAS)0-1002-Ulcer size3-Healing timeSumac paste led to the shortest healing time, smaller lesion size, and lower pain scores versus Triamcinolone and placebo and Triamcinolone had the longest healing time.Rhus coriaria gel20Placebo19Ghalwash et al., 2024/Egypt [32]60Single-blindedNM37Triamcinolone acetonide/0.1%151-Pain intensity (VAS)0-1002-Ulcer size3-Oral Health Impact Profile (OHIP-14)Thyme honey significantly reduced ulcer size compared to triamcinolone acetonide on days 5 and 7, with greater pain reduction on days 3, 5, and 7, and lower OHIP scores at day 7.Thyme honey15 Nayak et al., 2023/India [34]50Double-blinded18–604–510Triamcinolone acetonide/0.1%251-Pain intensity2-Ulcer size3-Ulcer severityTriamcinolone and Hiora SG gel showed significant reductions in pain, pain duration, and ulcer severity (p = 0.001), with no significant difference between themHiora SG gel25 Abbasi et al., 2023/Iran [35]60Double-blinded18–5037Triamcinolone acetonide/0.1%301-Healing time2-Time of Pain recoveryThe Salvizan group demonstrated a faster recovery, with shorter mean durations of pain relief and wound healing as well as compared with the triamcinolone acetonide group.Salvizan gel30 Umpreecha et al., 2023/ Thailand [36]72Double-blinded18–6537Triamcinolone acetonide/0.1%241-Pain intensity (VAS)0-1002-Ulcer size3-Ulcer severity4-quality-of-life questionnaire (OHIP-14).CBD and triamcinolone both reduced ulcer size more than placebo at all time points. CBD showed greater erythema reduction than placebo on day 2, while triamcinolone did so at all time points. Pain was lower with CBD vs placebo on day 5, and with triamcinolone vs placebo on days 4, 5, and 7. CBD group reported higher satisfaction, but OHIP-14 scores were similar across groupsTopical cannabidiol/0.1%24Placebo24 Lavaee, et al., 2022/Iran [37]22Single-blindedNM36Triamcinolone acetonide/0.1%111-Pain intensity (VAS)0-102-Ulcer sizeRhus coriaria and triamcinolone showed no significant intergroup differences, but both significantly reduced pain and lesion size; reductions were more consistent across all time points in the Rhus coriaria group.Rhus coriaria11Dhopte et al., 2022/India [38]60Unblinded15–50410Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Erythema4-Healing score5-Qulity of lifeBy day 3, the Low-level laser therapy group showed significantly greater pain and erythema reduction and better ulcer healing than the Triamcinolone group. Ulcer size reduction was similar between groups on days 3 and 5, with complete healing in both groups by day 10.1Low-level laser therapy/810 nm wavelength, 6.3 J/cm30Remash et al., 2021/India [39]30NA18–3037Triamcinolone acetonide/0.1%151-Pain intensity (NRS)2-Ulcer size3-Degree of ulcer healing4-Occurrence of New UlcersOn day 3, pre‑and probiotic sand hyaluronic acid had significantly lower pain scores than Hyaluronic acid and Triamcinolone (P = 0.04 and 0.01). By day 7, pre‑and probiotics and hyaluronic acid showed the highest wound closure (93.4 ± 2.5%) and greatest pain reduction (0.2 ± 0.42), but these differences were not statistically significant (P >0.05).3Hyaluronic acid/0.2%152Capsule of pre‑and probiotics & hyaluronic acid/0.2%15 Huo et al., 2021/China [40]56Unblinded18 and above 5133Triamcinolone acetonide/ 0.1%281-Pain intensity (VAS)0-102-Healing timeDiode laser reduced pain more effectively than Triamcinolone, with minimal advantage on wound healing comparing with Triamcinolone . .1Diode laser/wavelength of 810 nm and fiber diameter of 320 μm28 Seyyedi et al., 2020/ Iran [41]15Double-blinded17–6047Triamcinolone acetonide/0.1%51-Pain intensity (VAS)0-102-Ulcer sizeCO₂ laser (pulsed and continuous) reduced pain significantly effectively than Triamcinolone (P<0.05) but showed no significant effect on ulcer size.Continuous laser/power of 1 W and pulse duration of 5–10 s5Pulsed CO2 laser/power of 261 W and pulse duration of 180 ms5 Kia et al., 2020/Iran [42]58Double-blindedNM310Triamcinolone acetonide/0.1%29 1-Pain intensity (VAS)0-10 2-Ulcer sizeNo significant differences between the two groups in pain severity, lesion size.Curcumin/5 %29 Raman, et al., 2020/ India [43]69Unblinded18–3037Triamcinolone acetonide/0.1%351-Pain intensity (NIPC)0-5 2-Ulcer sizeTriamcinolone and Curcumin showed significant pain and size reduction (P<0.001).Curcumin/10mg34 Mirzaee et al., 2019/ Iran [44]60Triple-blindedNM47Triamcinolone acetonide/0.1%281-Pain intensity (VAS)0-1002-Ulcer sizePain intensity decreased in both NT and CT groups, with similar final scores. Lesion size reduced in both groups, but NT showed significantly greater reduction on days 2 & 4.Nanobased triamcinolone/0.1%27 Giroh et al., 2019/India [45]37Single‑blinded20–5037Triamcinolone acetonide/0.1%171-Pain intensity (VAS)0-102-Ulcer size3-Burning sensationTriamcinolone healed ulcers faster, while aloe vera gel provided better pain and burning relief.Topical aloe vera gel17 Tavangar et al., 2019/ Iran [46]60Double-blinded18–5035Triamcinolone acetonide/0.1%201-Ulcer size2-Healing time3-Time of Pain recoveryPunica granatum gel achieved faster pain relief compared with the placebo group, whereas the Triamcinolone group did not differ significantly from placebo. Furthermore, wound healing time was significantly shorter in the Punica granatum gel than in both the TriamcinolonePunica granatum gel20Placebo20 Sharma et al., 2018/India [47]50Double-blindedNM410Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer size3-Number ulcers4-Erythema 5-Exudate LevelsTriamcinolone acetonide 0.1% and amlexanox 5% were most effective in reducing ulcer size, number, pain, erythema, and exudate by days 8 and 10 (P=.000), outperforming doxycycline, benzocaine, and placebo. Doxycycline and benzocaine showed significant pain relief on the VAS scale.Amlexanox/5%10Benzocaine gel/20%10Doxycycline hyclate/100 mg10Placebo10 Shrivastava et al., 2018/India [48]40Double-blinded18–4545Triamcinolone acetonide/0.1%201-Pain intensity (VAS)0-102-Ulcer size3-Healing time4-ErythemaTriamcinolone had greater peri-ulcer erythema and pain reduction, while complete healing was slightly higher in the amlexanox groupAmlexanox 5%20 Ofluoglu et al., 2017/Turkey [11]180Doubleblinded18–6547Triamcinolone acetonide/0.1%601-Pain intensity (VAS)0-10 2-Ulcer sizeTGO group showed significantly lower pain scores on days 2, 4, and 6, with higher pain improvement rates on days 2 and 4, and greater ulcer size reduction on days 4 and 6 compared to the other groups. Demographics and ulcer history were similar across groups.Triester glycerol oxide60Placebo60NM Koray et al., 2016/Turkey [49]60UnblindedNM47Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-10Hyaluronic acid gel reduced RAS pain more effectively than TA, with significantly lower VAS scores on days 4 and 7.Hyaluronic acid30 Tadbir et al., 2015/Iran [50]43Double- blinded18–4636Triamcinolone acetonide/0.1%141-Pain intensity (VAS)2-Ulcer size3-Healing time4-Satisfaction of patients.Both triamcinolone and chamomile in Orabase reduced ulcer size by day 3 and pain by days 3 and 6 compared with placebo. Triamcinolone was more effective than chamomile and placebo in reducing ulcer size by day 6 and shortening healing time, while chamomile provided pain relief and high patient satisfaction.Chamomile14Placebo15 El-Haddad et al., 2014/Saudia Arabia [51]94Double- blinded18–6038Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Erythema4-Number of ulcersHoney significantly reduced ulcer size, pain duration, and erythema compared to topical corticosteroid and Orabase, with no reported side effects, confirming its effectiveness and safety for minor aphthous ulcers.Honey34Placebo30Deshmukh et al., 2014/India [52]60Double-blinded13–6637Triamcinolone acetonide/0.1%301-Pain intensity (VAS)0-102-Ulcer size3-Healing time4-Number of ulcersBoth groups showed significant improvement in ulcer size, pain, number, and duration over 7 days, but there was no significant difference between them in treating RAS.Curcumin/10mg30Halim, et al., 2014/Malaysia[53]20Single-blinded18 and above25Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer SizeNo significant differences were observed between groups, but virgin coconut oil showed a trend toward greater ulcer size reduction and pain relief compared to triamcinolone.Virgin coconut oil10Halim et al., 2013/Malaysia [54]20Single-blinded18 and above25Triamcinolone acetonide/0.1%101-Pain intensity (VAS)0-102-Ulcer sizeBoth treatments were equally effective in relieving pain and reducing the size of recurrent aphthous ulcers, with no significant differences between them.Turmeric powder10 Bhalang, et al., 2013/ Thailand [55]180Double-blinded18–6537Triamcinolone acetonide/0.1%601-Pain intensity (VAS)0-100 2-Ulcer sizeAcemannan caused no allergic reactions or side effects and showed better pain and ulcer size reduction than control, though less effective than 0.1% triamcinolone acetonide. Patient satisfaction was highest with triamcinolone and acemannan.Acemannan/0.560Placebo60 Characteristics of the studies included, presented in descending order 1-Pain intensity (VAS)0-100 2-Ulcer size 3-Healing time 1-Pain intensity (VAS)0-100 2-Ulcer size 3-Oral Health Impact Profile (OHIP-14) 1-Pain intensity 2-Ulcer size 3-Ulcer severity 1-Healing time 2-Time of Pain recovery 1-Pain intensity (VAS)0-100 2-Ulcer size 3-Ulcer severity 4-quality-of-life questionnaire (OHIP-14). 1-Pain intensity (VAS)0-10 2-Ulcer size 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Erythema 4-Healing score 5-Qulity of life 1-Pain intensity (NRS) 2-Ulcer size 3-Degree of ulcer healing 4-Occurrence of New Ulcers 1-Pain intensity (VAS)0-10 2-Healing time 1-Pain intensity (VAS)0-10 2-Ulcer size 1-Pain intensity (VAS)0-10 2-Ulcer size 1-Pain intensity (NIPC)0-5 2-Ulcer size 1-Pain intensity (VAS)0-100 2-Ulcer size 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Burning sensation 1-Ulcer size 2-Healing time 3-Time of Pain recovery 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Number ulcers 4-Erythema 5-Exudate Levels 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Healing time 4-Erythema 1-Pain intensity (VAS)0-10 2-Ulcer size 1-Pain intensity (VAS) 2-Ulcer size 3-Healing time 4-Satisfaction of patients. 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Erythema 4-Number of ulcers 1-Pain intensity (VAS)0-10 2-Ulcer size 3-Healing time 4-Number of ulcers 1-Pain intensity (VAS)0-10 2-Ulcer Size 1-Pain intensity (VAS)0-10 2-Ulcer size 1-Pain intensity (VAS)0-100 2-Ulcer size Intervention and control groups All trials employed 0.1% triamcinolone acetonide in paste or ointment form. Comparisons included sumac gel [33]; honey [32, 51]; HiOra SG gel [34]; Salvizan gel [35]; topical 0.1% cannabidiol [36]; Rhus coriaria [37]; laser therapy [38, 40, 41]; hyaluronic acid [39, 49]; curcumin gel [42, 43, 52]; nanobased triamcinolone gel [44]; topical aloe vera gel [45]; Punica granatum formulated gel [46]; 5% amlexanox, 20% benzocaine gel, and 100 mg of doxycycline hyclate [47]; topical 5% amlexanox [48]; triester glycerol oxide gel [11]; chamomile in Orabase [50]; virgin coconut oil [53], turmeric powder [54]; and 0.5% acemannan [55]. Eight studies had placebo groups [32, 36, 46, 47, 49, 50, 55]. Outcome measures The main outcome in 23 studies was pain intensity [11, 32–34, 36–55], that in 22 studies was ulcer size [11, 32–34, 36–39, 41–47, 49–54], and that in seven studies was healing time [33, 35, 40, 45, 48, 49, 51]. Other outcomes included the time of pain recovery [35, 45], the severity of ulcers [34, 36], satisfaction [36, 49], the number of ulcers [46, 50, 51], erythema [46, 47, 50], exudation [46], the quality of life [38], burning sensation [44], oral health impact profiles [32], the degree of ulcer healing, and the occurrence of new ulcers [39]. Risk of bias in included studies As shown in Table 3, three studies were evaluated as having a low risk of bias in every assessed domain [35, 42, 51]; 12 studies were considered as being of some concern [32, 33, 36, 37, 40, 41, 44, 46–48, 50, 52]; and 10 studies were considered as being of high risk [11, 32, 38, 39, 43, 45, 49, 53–55].Table 3Summary of risk of bias for each included study [11, 33–55] Table 3Summary of risk of bias for each included study [11, 33–55] Summary of risk of bias for each included study [11, 33–55] Main outcomes All studies evaluated the efficacy of triamcinolone in managing minor RAS primarily by comparing its pain-reducing effects with those of various alternatives. Pain reduction was consistently assessed across trials by using different measurement tools, including VAS. Specifically, several studies employed VAS ranging from 0 to 10 points [11, 37, 38, 40–42, 45, 47–54], whereas others used a 0–100 scale [32, 33, 36, 44, 55]. Additionally, pain assessment was conducted by employing a numerical rating scale [39] and the numeric intensity pain category [43]. In many of these trials, interventions involving 0.1% triamcinolone acetonide resulted in significantly greater pain reduction than those with alternatives, such as thyme honey [32, 51], sumac gel [33], HiOra gel [34], LLLT (810 nm at 6.3 J/cm²) [38], CO2 laser therapy [41], diode laser (810 nm) therapy [40], a combination of microbiome therapy with hyaluronic acid [39], aloe vera [45], triester glycerol oxide [11], and hyaluronic acid gel [49]. By contrast, the pain reduction obtained by several interventions, including cannabidiol [36], R. coriaria [36], hyaluronic acid [39], 5% curcumin [42, 43], nanobased triamcinolone gel [44], 5% amlexanox [47, 48], 10 mg of curcumin [52], virgin coconut oil [53], and turmeric powder [54], was comparable to that achieved with 0.1% triamcinolone acetonide. Conversely, the pain reduction observed with 100 mg of doxycycline hyclate combined with 20% benzocaine gel [47], chamomile in Orabase [48], and acemannan [55] was inferior to that acquired with 0.1% triamcinolone acetonide. Ulcer size reduction was significantly greater under interventions with thyme honey [32, 51], sumac gel [33], cannabidiol [36], nanobased triamcinolone gel [44], P. granatum [46], and triester glycerol oxide [11] than under 0.1% triamcinolone acetonide treatment. By contrast, the outcomes of R. coriaria [37], LLLT at 810 nm and 6.3 J/cm2 [38], CO2 laser therapy [41], 5% amlexanox [47, 48], curcumin [52], virgin coconut oil [53], and turmeric powder [54] were similar to those of 0.1% triamcinolone acetonide. However, the ulcer size reduction achieved with aloe vera [45], 100 mg of doxycycline hyclate combined with 20% benzocaine gel [46], chamomile in Orabase [47], and acemannan [58] was inferior to that achieved with 0.1% triamcinolone acetonide. Compared with those under 0.1% triamcinolone acetonide treatment, the healing times of RAS were shorter under treatment with diode lasers (810 nm) [40], P. granatum [46], and sumac gel [33]. However, the healing times under treatment with 0.1% triamcinolone acetonide and 5% amlexanox [48], chamomile in Orabase [50], and curcumin [52] were similar. Additionally, the time to pain recovery reduced under Salvizan treatment [35]. Other outcomes revealed that ulcer severity was lower under treatment with HiOra gel [33] and cannabidiol [36] and the duration of ulcer recovery was shorter under Salvizan treatment [35] than under 0.1% triamcinolone acetonide treatment. Patient satisfaction was higher under cannabidiol treatment [36] and LLLT [38] than under 0.1% triamcinolone acetonide treatment. The number of ulcers remained unchanged under treatment with 5% amlexanox [47] and curcumin [52] but reduced under treatment with 100 mg of doxycycline hyclate and 20% benzocaine gel [47]. Furthermore, compared with that under 0.1% triamcinolone acetonide treatment, erythema was lower under cannabidiol [36] and honey [51] treatment; similar to that under 5% amlexanox [47]; and higher under treatment with 100 mg of doxycycline hyclate and 20% benzocaine gel [47]. Exudation remained unchanged under 5% amlexanox treatment [47] but was higher under treatment with 100 mg of doxycycline hyclate combined with 20% benzocaine gel [47] than under 0.1% triamcinolone acetonide. Healing scores under LLLT [38] were superior to those under 0.1% triamcinolone acetonide treatment. However, quality-of-life measures were similar under the different treatments. Finally, burning sensation was lower under aloe vera treatment [45] than under 0.1% triamcinolone acetonide treatment. Meta-analysis for pain reduction under triamcinolone acetonide treatment versus that under hyaluronic acid treatment An inverse-variance, random-effects meta-analysis based on two studies was conducted to assess the effectiveness of 0.1% triamcinolone acetonide versus that of hyaluronic acid in pain reduction by Day 7 [39, 49]. The findings showed no statistically significant improvement in pain reduction by Day 7 with a mean difference (MD) of 0.29 VAS and a confidence interval (CI) of − 0.66–1.24 (P < 0.55). The following results for heterogeneity, as shown in Fig. 2, were obtained: χ2 = 7.29, P = 0.007; I2 = 86%. Fig. 2Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus that under 0.2% hyaluronic acid treatment Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus that under 0.2% hyaluronic acid treatment Meta-analysis for pain reduction under 0.1% triamcinolone acetonide treatment versus that under other treatments Meta-analysis was conducted on the basis of two studies to evaluate the efficacy of 0.1% triamcinolone acetonide in reducing pain on Day 7 compared with that of other treatments [39, 42, 49]. Pooled analysis revealed no statistically significant MD in pain scores favoring triamcinolone acetonide (MD = 0.39 VAS; 95% CI: −0.30–1.90; P = 0.27). As shown in Fig. 3, the following results for heterogeneity were obtained: χ2 = 7.80, P = 0.02; I2 = 74%. Fig. 3Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus other treatments Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus other treatments Meta-analysis for pain reduction under 0.1% triamcinolone acetonide treatment versus that under the placebo This meta-analysis included two studies evaluating the effect on pain reduction of 0.1% triamcinolone acetonide versus that of the placebo on Day 7 [33, 39]. The pooled MD obtained by using a random-effects model was 0.16 VAS (95% CI: −0.16–0.47, P = 0.33), indicating no statistically significant difference between triamcinolone and the placebo. As shown in Fig. 4, heterogeneity was low (χ2 = 0.80, P = 0.37; I2 = 0%), suggesting consistency between studies. Fig. 4Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus placebo Forest plot of pain reduction under 0.1% triamcinolone acetonide treatment versus placebo Meta-analysis for ulcer size reduction under 0.1% triamcinolone acetonide treatment versus that under other treatments The meta-analysis comparing the effect of triamcinolone acetonide with that of other treatments on ulcer size reduction on Day 7 was based on six studies [32, 33, 39, 42–44]. Pooled analysis with a random-effects model revealed a statistically significant MD that indicated the superiority of triamcinolone (MD = 0.72 mm, 95% CI: 0.33–1.10, P = 0.0003). As shown in Fig. 5, the following results were obtained for heterogeneity: (χ2 = 9.72, P = 0.08; I2 = 49%). Fig. 5Forest plot of ulcer size reduction under 0.1% triamcinolone acetonide treatment versus other treatments Forest plot of ulcer size reduction under 0.1% triamcinolone acetonide treatment versus other treatments Meta-analysis for healing time under 0.1% triamcinolone acetonide treatment versus that under other treatments A random-effects meta-analysis of four controlled trials comparing intralesional 0.1% triamcinolone acetonide with various alternative treatments on Day 7 revealed that triamcinolone had an advantage across studies [33, 35, 40, 46]. The pooled MD was 1.12 days (95% CI: 0.51–1.73; Z = 3.61, P = 0.0003), indicating that triamcinolone has a statistically significant benefit over other treatments. Figure 6 shows that the following results were obtained for heterogeneity: χ2 = 27.45, P = 0.00001; I2 = 89%. Fig. 6Forest plot of healing time under 0.1% triamcinolone acetonide treatment versus other treatment Forest plot of healing time under 0.1% triamcinolone acetonide treatment versus other treatment Meta-analysis of healing time under 0.1% triamcinolone acetonide treatment versus that under the placebo An inverse-variance, random-effects meta-analysis based on two studies was conducted to assess the effectiveness of 0.1% triamcinolone acetonide in reducing healing time on Day 7 [33, 46]. The pooled results indicated that compared with the control, triamcinolone was associated with a greater mean reduction in healing time, with an MD of 1.95 days (95% CI: −0.92–4.82). However, this difference was not statistically significant (P = 0.18). Substantial heterogeneity was observed across the studies (χ2 = 20.32, P < 0.00001; I2 = 95%), as shown in Fig. 7. Fig. 7Forest plot of healing time under 0.1% triamcinolone acetonide treatment versus placebo Forest plot of healing time under 0.1% triamcinolone acetonide treatment versus placebo Discussion This systematic review and meta-analysis synthesized data from 25 RCTs to evaluate the efficacy of 0.1% triamcinolone acetonide in the management of minor RAS. Its results indicate that 0.1% triamcinolone acetonide conferred modest but measurable benefits in ulcer size reduction and healing time, whereas its effect on pain reduction, a primary concern for patients, was not consistently superior to that of the placebo or other active treatments. These findings align with the pharmacological profile of triamcinolone acetonide as a corticosteroid with strong anti-inflammatory properties but limited direct analgesic activity [23]. Earlier reviews had a limited scope, focusing on and analyzing herbal therapies [60] and laser therapy only [56–58]. The present systematic review represents the first fully quantitative synthesis of 25 RCTs comparing 0.1% triamcinolone acetonide with other therapeutic options for minor RAS. Three trials reporting the pain intensity of RAS described reduction after the application of LLLT (810 nm at 6.3 J/cm2) [38] and CO2 laser [41] and diode laser (810 nm) therapies [40]. Pain reduction under these therapies was superior to that under 0.1% triamcinolone acetonide treatment. Moreover, 0.1% triamcinolone acetonide treatment had similar efficacy in ulcer size reduction as LLLT at 810 nm and 6.3 J/cm2 [38] and CO2 laser therapy [41]. One study showed that the healing time under diode laser (810 nm) treatment was shortened [40]. This treatment is extensively employed for various oral conditions and precancerous lesions, such as radiation and chemotherapy-induced oral mucositis [59–64]. Through the precise control of their wavelength and power, lasers can induce localized metabolic events via multiple physical and chemical processes [65–68], resulting in analgesic, anti-inflammatory, and healing effects without causing thermal damage. This aspect accounts for their role in the treatment of RAS [56–58, 68]. Furthermore, daily assessments have confirmed the safety of laser therapy, although remarkable short-term abnormalities have been observed. A recent retrospective review conducted by Suter et al. [69] underscores the advantages of laser therapy over other local interventions. These advantages include its brief treatment duration, substantial pain relief, and enhanced safety profile given that no major adverse events or abnormalities in blood tests were reported. Consequently, laser therapy is recommended for patients who are intolerant of steroids or experiencing severe pain. Employing laser therapy as a short-term intervention to expedite healing and alleviate pain during exacerbations is advised [70]. Although topical medications offer therapeutic benefits, their effectiveness can be compromised by limited retention at the application site. This shortened contact time is primarily due to the continuous flushing action of saliva and may reduce the overall efficacy of the above therapies in promoting ulcer healing [71, 72]. The clinical importance of this work’s results warrants careful interpretation. The mean ulcer size reduction (0.72 mm) and shortened healing time (1.12 days) may appear minor in absolute terms. However, for recurrent lesions that impair eating and speaking, the aforementioned improvements can cumulatively enhance patient comfort and reduce dependence on symptomatic therapies. Nevertheless, the lack of a statistically significant advantage of triamcinolone acetonide in pain reduction relative to the placebo challenges the assumption that triamcinolone acetonide should remain the default first-line topical agent for RAS management. Alternative therapies, including curcumin [42, 43, 52], honey-based gels [32], and hyaluronic acid [49], have shown comparable or superior pain relief to triamcinolone acetonide, whereas laser therapy demonstrated greater analgesic benefit than triamcinolone acetonide in several RCTs [38, 40, 41]. For patients intolerant to corticosteroids or in cases where rapid pain control is prioritized, these options may represent effective interventions [56–58, 69, 70]. The magnitude of these observed effects holds clinical importance. The average ulcer size reduction of 0.72 mm (95% CI 0.33–1.10) of minor RAS results in visibly shrunken lesions and potentially reduced irritation during oral function. Similarly, the mean reduction of 1.12 day in healing times (95% CI 0.51–1.73) represents the accelerated resolution of symptoms. Although these improvements may appear modest in absolute terms, for a recurrent and painful condition such as RAS, even small accelerations in healing can improve comfort, allow the early resumption of eating and speaking, and reduce reliance on analgesics or adjunctive therapies. When multiplied across multiple ulcer episodes per year, such benefits can meaningfully enhance patients’ quality of life. Among the 10 studies included in the meta-analysis, two [35, 42] were rated as low risk across all ROB2 domains, enhancing the reliability of their findings. However, three studies [34, 43, 49] were judged to have a high overall risk of bias, primarily because of issues in randomization and selective outcome reporting. The remaining five studies were considered to be of some concern [32, 33, 40, 44, 46], particularly in domains related to deviations from intended interventions and the selection of reported results. The inclusion of high-risk studies may have affected the pooled estimates, and findings should thus be interpreted with caution. Strengths and limitations of this review Despite the widespread use of 0.1% triamcinolone acetonide for minor RAS, to our knowledge, no prior systematic review has comprehensively evaluated its efficacy compared with those of other active and placebo treatments across multiple outcome domains. Several limitations of this work should be noted. First, the heterogeneity of intervention protocols, dosing schedules, and outcome assessment tools may have introduced variability. Second, the small number of studies in some meta-analyses reduced statistical power and limited subgroup analyses. Third, the methodological quality of many included trials was suboptimal, with only three studies rated as low risk of bias. forth, reporting inconsistencies and missing data in primary studies may have affected the synthesis of results. Finally, Variation among studies in intervention types, treatment duration, patient populations, and outcome measures contributed to substantial heterogeneity, which may have affected the precision and generalizability of the pooled findings. Implications for practice For patients with contraindications to corticosteroids—such as individuals with systemic fungal infections, uncontrolled diabetes, or a history of hypersensitivity reactions—natural agents like thyme honey, hyaluronic acid, and curcumin may be effective and safe alternatives. Furthermore, LLLT may be considered in cases of recurrent or severe ulcers, especially when rapid pain relief is desired or when conventional topical therapies have failed. Implications for future research Future RCTs evaluating RAS treatments should ensure robust randomization procedures and clearly report allocation concealment methods. Several studies in the present review lacked blinding or used unclear blinding protocols. This inadequacy may have influenced subjective outcomes like pain assessment. Moreover, the selective reporting of outcomes and missing data were common limitations. Research on comparative effectiveness involving patient-centered outcomes, such as quality of life and satisfaction, should be prioritized. Moreover, network meta-analyses may provide a clear hierarchy of interventions for the management of minor RAS. Conclusion The findings of this study offer a promising shift in the management of RAS. Natural agents like honey, sage, and sumac gel are more effective and safer alternatives to conventional corticosteroids, such as triamcinolone. For patients who are intolerant to corticosteroids or experience frequent recurrences, these natural treatments may serve as viable first-line therapies. In severe cases, integrating laser therapy could enhance outcomes. Meanwhile, emerging options, such as hyaluronic acid with microbiome formulations and triester glycerol oxide, present exciting avenues that merit additional clinical research. This meta-analysis demonstrated that triamcinolone significantly reduced ulcer size compared with thyme honey, R. coriaria gel, and nanobased triamcinolone and shortened healing time compared with Salvizan and P. granatum gels. However, triamcinolone showed no significant effect on pain reduction when compared with either other treatments or the placebo and on healing time when compared with the placebo. This apparent discrepancy may be attributed to the limited number of placebo-controlled trials included in this work. Moreover, most of the studies encompassed by this meta-analysis were judged to be at some of concern, with some presenting a high risk of bias. These limitations should be considered when interpreting the findings of this work. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.